

Guangxi Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8961643/publications.pdf>

Version: 2024-02-01

48
papers

579
citations

623734

14
h-index

677142

22
g-index

52
all docs

52
docs citations

52
times ranked

897
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate. <i>BJU International</i> , 2022, 129, 345-355.	2.5	18
2	Efficacy of second-line ICI combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study. <i>Immunotherapy</i> , 2022, 14, 309-320.	2.0	0
3	Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1734-1743.	7.0	54
4	Is Additional Systematic Biopsy Necessary in All Initial Prostate Biopsy Patients With Abnormal MRI?. <i>Frontiers in Oncology</i> , 2021, 11, 643051.	2.8	4
5	Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients. <i>Prostate</i> , 2021, 81, 721-727.	2.3	15
6	Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abiraterone. <i>Cancer Medicine</i> , 2021, 10, 6282-6290.	2.8	8
7	The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2021, 81, 1191-1201.	2.3	9
8	Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 6833-6845.	1.9	4
9	Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 5262.	12.8	40
10	Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 789319.	3.5	9
11	Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma. <i>Cancer Medicine</i> , 2020, 9, 959-970.	2.8	14
12	Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 519388.	2.8	18
13	Survival Outcomes of Radical Prostatectomy + Extended Pelvic Lymph Node Dissection and Radiotherapy in Prostate Cancer Patients With a Risk of Lymph Node Invasion Over 5%: A Population-Based Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 607576.	2.8	4
14	The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors. <i>Cancer Control</i> , 2020, 27, 107327482097714.	1.8	2
15	The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1454-1463.	1.3	2
16	MicroRNA-106a suppresses prostate cancer proliferation, migration and invasion by targeting tumor-derived IL-8. <i>Translational Cancer Research</i> , 2020, 9, 3507-3517.	1.0	3
17	The AKR1C3/AR ϵ 7 complex maintains CRPC tumour growth by repressing B4GALT1 expression. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12032-12043.	3.6	13
18	The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 42.	1.9	32

#	ARTICLE	IF	CITATIONS
19	The effect of AKR1C3 on the switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients receiving abiraterone.. Journal of Clinical Oncology, 2020, 38, 133-133.	1.6	1
20	High-exosomal AKR1C3 mRNA expression as a marker of poor efficacy of abiraterone in metastatic PCa patients.. Journal of Clinical Oncology, 2020, 38, 196-196.	1.6	0
21	Exosomal TUBB3 mRNA expression level to predict prognosis for abiraterone treatment in metastatic prostate patients.. Journal of Clinical Oncology, 2020, 38, 244-244.	1.6	0
22	The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2020, 38, 369-369.	1.6	0
23	Genomic landscape and immune microenvironment features of FH-deficient renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 717-717.	1.6	0
24	Distinctive landscape of genetic mutation in patients with intraductal carcinoma of the prostate (IDC-P).. Journal of Clinical Oncology, 2020, 38, 192-192.	1.6	0
25	Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinoma. American Journal of Translational Research (discontinued), 2020, 12, 5416-5432.	0.0	4
26	The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma. Neoplasia, 2019, 21, 921-931.	5.3	16
27	Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?. Prostate, 2019, 79, 1673-1682.	2.3	7
28	AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy. Prostate, 2019, 79, 1553-1562.	2.3	22
29	The validation of the 2014 International Society of Urological Pathology (ISUP) grading system for patients with high-risk prostate cancer: a single-center retrospective study. Cancer Management and Research, 2019, Volume 11, 6521-6529.	1.9	3
30	The prognosis benefits of adjuvant versus salvage radiotherapy for patients after radical prostatectomy with adverse pathological features: a systematic review and meta-analysis. Radiation Oncology, 2019, 14, 197.	2.7	4
31	Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. BMC Cancer, 2019, 19, 360.	2.6	52
32	Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database. Scientific Reports, 2019, 9, 17985.	3.3	19
33	Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma. BMC Cancer, 2019, 19, 49.	2.6	21
34	The Prognostic Value of the Proportion and Architectural Patterns of Intraductal Carcinoma of the Prostate in Patients with De Novo Metastatic Prostate Cancer. Journal of Urology, 2019, 201, 759-768.	0.4	19
35	Adiponectin-AdipoR1 axis in renal cell carcinoma plays a pivotal role in tumor progression and drug resistance.. Journal of Clinical Oncology, 2019, 37, 634-634.	1.6	1
36	Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis. International Journal of Surgery, 2018, 52, 214-220.	2.7	9

#	ARTICLE	IF	CITATIONS
37	The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 9061-9070.	2.0	3
38	What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 505-517.	1.6	11
39	Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2018, 9, 3303-3310.	2.5	28
40	Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with <i>de novo</i> bone metastatic prostate cancer. <i>BJU International</i> , 2018, 122, 994-1002.	2.5	16
41	Therapeutic Potential of Human Adipose-Derived Stem Cell Exosomes in Stress Urinary Incontinence – An in Vitro and in Vivo Study. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 1710-1722.	1.6	46
42	Is it the time to shift paradigms in castration naïve prostate cancer (CNPC): A meta-analysis of upfront docetaxel and abiraterone in men with CNPC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 360-360.	1.6	1
43	Will second-line nonsteroidal antiandrogen drugs (NSAA) after the failure of bicalutamide affect the therapeutic efficacy of the sequential abiraterone treatment?. <i>Journal of Clinical Oncology</i> , 2018, 36, 337-337.	1.6	0
44	Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with <i>de novo</i> bone-metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 336-336.	1.6	0
45	The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgen-deprivation therapy in high-risk prostate cancer following radical prostatectomy. <i>Prostate</i> , 2017, 77, 1279-1287.	2.3	16
46	The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy. <i>Oncotarget</i> , 2017, 8, 55374-55383.	1.8	30
47	The prognostic role of IDC-P in mCRPC and its predictive value in those treated with docetaxel or abiraterone as first-line therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e603-e603.	1.6	1
48	The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgen-deprivation therapy in high-risk prostate cancer following radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e595-e595.	1.6	0